BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

38 related articles for article (PubMed ID: 25338967)

  • 1. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation.
    Cashen AF; Dehdashti F; Luo J; Homb A; Siegel BA; Bartlett NL
    J Nucl Med; 2011 Mar; 52(3):386-92. PubMed ID: 21321279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.
    Horwitz S; Coiffier B; Foss F; Prince HM; Sokol L; Greenwood M; Caballero D; Morschhauser F; Pinter-Brown L; Iyer SP; Shustov A; Nichols J; Balser J; Balser B; Pro B
    Ann Oncol; 2015 Apr; 26(4):774-779. PubMed ID: 25605745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18-Fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of 'indeterminate' reports.
    Thomas A; Gingrich RD; Smith BJ; Jacobus L; Ristow K; Allmer C; Maurer MJ; Habermann TM; Link BK
    Leuk Lymphoma; 2010 Mar; 51(3):439-46. PubMed ID: 20141442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arterial effects of anthracycline: structural and inflammatory assessments in non-human primates and lymphoma patients using
    Rankin S; Fountain C; Gemmell AJ; Quinn D; Henderson A; McClure J; Small S; Venugopal B; McKay P; Slomka PJ; Colville D; Petrie MC; Meléndez GC; Lang NN
    bioRxiv; 2024 Jun; ():. PubMed ID: 38895275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: the intergroup trial JCOG0803/WJOG4307L.
    Abe T; Takeda K; Ohe Y; Kudoh S; Ichinose Y; Okamoto H; Yamamoto N; Yoshioka H; Minato K; Sawa T; Iwamoto Y; Saka H; Mizusawa J; Shibata T; Nakamura S; Ando M; Yokoyama A; Nakagawa K; Saijo N; Tamura T
    J Clin Oncol; 2015 Feb; 33(6):575-81. PubMed ID: 25584004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to Sequence Therapies in Peripheral T Cell Lymphoma.
    Wudhikarn K; Bennani NN
    Curr Treat Options Oncol; 2021 Jul; 22(9):74. PubMed ID: 34213653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort.
    Martinez-Calle N; Kirkwood AA; Lamb M; Smith A; Khwaja J; Manos K; Shrubsole C; Gray N; Lewis K; Tivey A; Bishton MJ; Hawkes E; Ahearne MJ; Osborne W; Collins GP; Illidge T; Linton KM; Cwynarski K; Burton C; Fox CP
    Adv Ther; 2021 Jul; 38(7):3789-3802. PubMed ID: 34037958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controversies in the Treatment of Peripheral T-cell Lymphoma.
    Bachy E; Broccoli A; Dearden C; de Leval L; Gaulard P; Koch R; Morschhauser F; Trümper L; Zinzani PL
    Hemasphere; 2020 Oct; 4(5):e461. PubMed ID: 33062943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.
    Aldin A; Umlauff L; Estcourt LJ; Collins G; Moons KG; Engert A; Kobe C; von Tresckow B; Haque M; Foroutan F; Kreuzberger N; Trivella M; Skoetz N
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012643. PubMed ID: 31930780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of FDG-PET/CT in determining upfront autologous stem cell transplantation for the treatment of peripheral T cell lymphomas.
    Ahn SY; Jung SY; Jung SH; Ahn JS; Lee JJ; Kim HJ; Kang SR; Han YH; Kwak JY; Yhim HY; Yang DH
    Ann Hematol; 2020 Jan; 99(1):83-91. PubMed ID: 31807859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.
    Aldin A; Umlauff L; Estcourt LJ; Collins G; Moons KG; Engert A; Kobe C; von Tresckow B; Haque M; Foroutan F; Kreuzberger N; Trivella M; Skoetz N
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD012643. PubMed ID: 31525824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma.
    Mehta-Shah N; Ito K; Bantilan K; Moskowitz AJ; Sauter C; Horwitz SM; Schöder H
    Blood Adv; 2019 Jan; 3(2):187-197. PubMed ID: 30670535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of 18-FDG positron emission tomography in T cell non-Hodgkin lymphoma.
    Eslick R; Dunlop L; Lin M; Hsu D; Ling S
    Blood Cancer J; 2017 Apr; 7(4):e556. PubMed ID: 28430171
    [No Abstract]   [Full Text] [Related]  

  • 15. Post-therapy ¹⁸F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T cell lymphoma.
    Tomita N; Hattori Y; Fujisawa S; Hashimoto C; Taguchi J; Takasaki H; Sakai R; Tateishi U; Ishigatsubo Y
    Ann Hematol; 2015 Mar; 94(3):431-6. PubMed ID: 25338967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients.
    El-Galaly TC; Pedersen MB; Hutchings M; Mylam KJ; Madsen J; Gang AO; Bøgsted M; de Nully Brown P; Loft A; Nielsen AL; Hendel HW; Iyer V; Gormsen LC
    Am J Hematol; 2015 Nov; 90(11):975-80. PubMed ID: 26201505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Qiao W; Zhao J; Wang C; Wang T; Xing Y
    Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin.
    Shibata Y; Hara T; Kasahara S; Yamada T; Sawada M; Mabuchi R; Matsumoto T; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Kito Y; Goto N; Miyazaki T; Takami T; Takeuchi T; Shimizu M; Tsurumi H
    Hematol Oncol; 2017 Jun; 35(2):163-171. PubMed ID: 26449182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should patients with aggressive peripheral T-cell lymphoma all be treated the same?: no... well yes, ...but maybe not for long.
    Moskowitz AJ; Lunning MA; Horwitz SM
    Cancer J; 2012; 18(5):445-9. PubMed ID: 23006950
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.